ReviewWorld journal of gastroenterology2015
High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment.
Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Trial
- Global Burden of Peptic Ulcer Disease (1990-2021) and Projections to 2050: A Comprehensive Analysis of Age, Sex, and Socioeconomic Disparities.Current medical science · 2026Article
- Efficacy and Safety of Tegoprazan inPharmaceuticals (Basel, Switzerland) · 2026Review
- Research Status and Prospects ofGastroenterology research and practice · 2026Review
- Tegoprazan-Containing Versus Proton Pump Inhibitor-Containing Therapy for First-Line Eradication ofJGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Immunoinformatic strategy for developing multi-epitope subunit vaccine against Helicobacter pylori.PloS one · 2025Article
- Analysis of Helicobacter pylori resistance in patients with different gastric diseases.Scientific reports · 2024Article
- An Overview of Selected Bacterial Infections in Cancer, Their Virulence Factors, and Some Aspects of Infection Management.Biology · 2023Review
- Antimicrobial Resistance Molecular Mechanisms ofAntibiotics (Basel, Switzerland) · 2023Article
- The Anti-Helicobacter pylori effects of Limosilactobacillus reuteri strain 2892 isolated from Camel milk in C57BL/6 mice.World journal of microbiology & biotechnology · 2023Article
- CMTM3 protects the gastric epithelial cells from apoptosis and promotes IL-8 by stabilizing NEMO during Helicobacter pylori infection.Gut pathogens · 2023Article
- Phytochemical Investigation ofMolecules (Basel, Switzerland) · 2022Article
- A Survey ofAntimicrobial agents and chemotherapy · 2022Article
- Clinical Factors Implicated in Antibiotic Resistance inMicroorganisms · 2022Review
- Effectiveness and Safety of Rifaximin-Containing Regimens forInfection and drug resistance · 2022Review
- Article
- The influence of P-glycoprotein expression in the standard treatment of Helicobacter pylori infection in Sprague Dawley rats.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2021Article
- Efficacy and safety of Zuojin Pill for chronic gastritis: Protocol for a systematic review of randomized controlled trials.Medicine · 2020Article
- Targeting the Protein Tunnels of the Urease Accessory Complex: A Theoretical Investigation.Molecules (Basel, Switzerland) · 2020Article
- Helicobacter pylori recrudescence and its influencing factors.Journal of cellular and molecular medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori (H. pylori) infection is associated with a variety of upper gastrointestinal diseases, including gastric cancer. With the wide application of antibiotics in H. pylori eradication treatment, drug-resistant strains of H. pylori are increasing. H. pylori eradication treatment failure affects the outcome of a variety of diseases of the upper gastrointestinal tract. Therefore, antibiotic resistance that affects H. pylori eradication treatment is a challenging situation for clinicians. The ideal H. pylori eradication therapy should be safe, effective, simple, and economical. The eradication rate of triple antibiotic therapy is currently less than 80% in most parts of the world. Antibiotic resistance is the main reason for treatment failure, therefore the standard triple regimen is no longer suitable as a first-line treatment in most regions. H. pylori eradication treatment may fail for a number of reasons, including H. pylori strain factors, host factors, environmental factors, and inappropriate treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.